SCHEMBL20205890

SCHEMBL20205890

CCN1CCC(C)(NC(=O)c2cc(Cl)ccc2C)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
RET P07949 1/20 0.43
CCR3 P51677 1/20 0.40
DRD2 P14416 2/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
MCHR1 Q99705 2/20 0.39
TP53 P04637 1/20 0.39
GHSR Q92847 1/20 0.39
MMP1 P03956 1/20 0.38
MMP9 P14780 1/20 0.38
MMP13 P45452 1/20 0.38
ADAM17 P78536 1/20 0.38
DRD1 P21728 1/20 0.38
CNR2 P34972 1/20 0.38
F10 P00742 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069660 0.86 P2RX7 (0.46) LMNARETDRD2TP53GHSR
SCHEMBL21651991 0.85 CCR3 (0.49) RETCCR3DRD2
SCHEMBL20158862 0.85 RET (0.42) RETCCR3CNR2KMT2ACCR8
SCHEMBL25503767 0.83 MCHR1 (0.47) MAPTLMNAALDH1A1RETCCR3
SCHEMBL20147579 0.83 F10 (0.41) RETDRD2DRD1CNR2F10
SCHEMBL21652015 0.79 CHRM5 (0.53) MAPTLMNAALDH1A1CCR3DRD2
SCHEMBL20205892 0.78 MT-CO2 (0.46) RETCCR3MEN1KMT2ATHRB
SCHEMBL21652023 0.78 CCR3 (0.49) MAPTLMNAALDH1A1RETCCR3
SCHEMBL25504246 0.78 RET (0.43) MAPTRETCCR3DRD2P2RX7
SCHEMBL21652022 0.77 CCR3 (0.50) LMNARETCCR3DRD2P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 MAPT 1499/4885LMNA 1968/4885ALDH1A1 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.